Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bruce Mosley is active.

Publication


Featured researches published by Bruce Mosley.


Journal of Biological Chemistry | 1996

Dual Oncostatin M (OSM) Receptors CLONING AND CHARACTERIZATION OF AN ALTERNATIVE SIGNALING SUBUNIT CONFERRING OSM-SPECIFIC RECEPTOR ACTIVATION

Bruce Mosley; Cyr De Imus; Della Friend; Norman Boiani; Bettina Thoma; Linda S. Park; David Cosman

Oncostatin M (OSM) is a cytokine whose structural and functional features are similar to other members of the interleukin (IL)-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor (LIF), granulocyte colonystimulating factor, ciliary neurotrophic factor, and cardiotrophin-1), many of which utilize gp130 as a common receptor subunit. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. This LIFR·gp130 complex is also a functional receptor for LIF. We have cloned and characterized an alternative subunit (OSMRβ) for an OSM receptor complex (a heterodimer of gp130 and OSMRβ) that is activated by OSM but not by LIF. The signaling capability of specific receptor subunit combinations was analyzed by independent assays measuring cell proliferation or induction of acute phase protein synthesis. Our results demonstrate that both LIF and OSM cause tyrosine phosphorylation and activation of the gp130·LIFR combination, but the gp130·OSMRβ complex is activated by OSM only. OSM-induced cellular responses, initiated through low affinity binding to gp130, are mediated by two heterodimeric receptor complexes that utilize alternative signal transducing subunits that confer different cytokine specificities to the receptor complex.


Journal of Biological Chemistry | 1997

Influence of Subunit Combinations on Signaling by Receptors for Oncostatin M, Leukemia Inhibitory Factor, and Interleukin-6*

Karen K. Kuropatwinski; Cyr De Imus; David P. Gearing; Heinz Baumann; Bruce Mosley

Oncostatin M (OSM), leukemia inhibitory factor (LIF), and interleukin-6 (IL-6) induce expression of a similar set of acute phase plasma protein genes in hepatic cells. The redundant action of these cytokines has been ascribed to the involvement of the common signal-transducing receptor subunit, gp130, in combination with cytokine-specific, ligand-binding subunits. To define the specificity of the signal transduction by the LIF/OSM receptor (a heterodimer of gp130 and LIF receptor (LIFR)) and the OSM-specific receptor (a heterodimer of gp130 and OSM receptor (OSMR)), we reconstituted the receptor function by transfection into receptor-negative Hep3B hepatoma cells. Both receptors activate DNA binding activity of STAT1, -3, and -5B and induce gene transcription through IL-6-responsive elements. The signaling-competent cytoplasmic domain regions of OSMR and LIFR were defined by the analysis of progressive carboxyl-terminal deletion constructs. The 36 residue carboxyl-terminal region containing the distal box 3 sequence motif of OSMR is required for signal transduction by the OSM-specific receptor. In contrast, signaling by LIFR did not display the same requirement for receptor domains and was not strictly dependent on the box 3 elements. The signaling by endogenous LIF and OSM receptors differed from that by IL-6R by the prominent activation of STAT5 as shown in the mouse hepatoma cell line, Hepa-1. The data suggest that the signaling specificity of the receptors for the three cytokines is determined by the composition of the cytoplasmic domains associated in the signal-competent receptor complex and that the signaling is not identical among these cytokine receptors.


Journal of Biological Chemistry | 1987

The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor.

Bruce Mosley; D L Urdal; K S Prickett; A Larsen; David Cosman; Paul J. Conlon; Steven Gillis; Steven K. Dower


Archive | 1989

Interleukin-4 receptors

David Cosman; Linda Park; Bruce Mosley; Patricia Beckmann; Carl J. March; Rejean L. Idzerda


Archive | 1991

Type II interleukin-1 receptors

John E. Sims; David Cosman; Stephen D. Lupton; Bruce Mosley; Steven K. Dower


Journal of Biological Chemistry | 1993

Reconstitution of the response to leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in hepatoma cells.

Heinz Baumann; Steven F. Ziegler; Bruce Mosley; Karen K. Morella; S Pajovic; David P. Gearing


Proceedings of the National Academy of Sciences of the United States of America | 1994

Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor

David P. Gearing; Steven F. Ziegler; Michael R. Comeau; Della Friend; Bettina Thoma; David Cosman; Linda Park; Bruce Mosley


Proceedings of the National Academy of Sciences of the United States of America | 1987

Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta.

Bruce Mosley; Steven K. Dower; Steven Gillis; David Cosman


Archive | 1995

RECEPTOR FOR ONCOSTATIN M

Bruce Mosley; David Cosman


Archive | 1993

DNA encoding type II interleukin-1 receptors

John E. Sims; David Cosman; Stephen D. Lupton; Bruce Mosley; Steven K. Dower

Collaboration


Dive into the Bruce Mosley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David P. Gearing

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge